Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
October 10, 2024 07:00 ET
|
Aclarion, Inc.
Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare...
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
September 27, 2024 06:57 ET
|
Aclarion, Inc.
Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify...
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
September 12, 2024 06:57 ET
|
Aclarion, Inc.
Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with proven path toward standard of care addressing...
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
September 10, 2024 06:57 ET
|
Aclarion, Inc.
Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial...
Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
September 05, 2024 06:57 ET
|
Aclarion, Inc.
Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population ...
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey
August 29, 2024 06:57 ET
|
Aclarion, Inc.
CLUE is a Multi-center Trial to Identify how Often Nociscan’s AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at...
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans
August 21, 2024 07:57 ET
|
Aclarion, Inc.
Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data Multiple Physicians and Sites Will Enroll in CLUE...
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
August 15, 2024 09:48 ET
|
Aclarion, Inc.
BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary...
Aclarion Announces First Commercial Agreement in Michigan
August 14, 2024 08:08 ET
|
Aclarion, Inc.
Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan Agreement Expands Nociscan Access to John Keller, MD, a Leading Neurosurgeon and Aclarion Medical Advisor,...
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
August 13, 2024 09:07 ET
|
Aclarion, Inc.
Vitality is a top 4 Provider of Private Medical Insurance in the UK.Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health Insurers in the UK.Nearly 60% of all Patients With Private...